{
  "guideline": {
    "id": "PA166182766",
    "name": "Annotation of FDA Label for fosphenytoin and CYP2C19, CYP2C9, HLA-B",
    "objCls": "Label Annotation",
    "source": "FDA",
    "version": 11,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166182766",
    "relatedChemicals": [
      {
        "id": "PA164746820",
        "name": "fosphenytoin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      },
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      },
      {
        "id": "PA35056",
        "name": "major histocompatibility complex, class I, B",
        "symbol": "HLA-B"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166311721",
      "name": "Recommendation Annotation PA166311721",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215900,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311674",
      "name": "Recommendation Annotation PA166311674",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215854,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311685",
      "name": "Recommendation Annotation PA166311685",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215864,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers. Should CEREBYX [fosphenytoin] be utilized for CYP2C9*3 carriers, consider starting at the lower end of the dosage range...[P]atients who are known to be intermediate or poor metabolizers may ultimately require lower doses to maintain similar steady-state concentrations compared to normal metabolizers. In patients who are known to be carriers of the decreased function CYP2C9*2 or *3 alleles (intermediate and poor metabolizers), consider starting at the low end of the dosage range and monitor serum concentrations to maintain total phenytoin concentrations of 10 to 20 mcg/mL.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311672",
      "name": "Recommendation Annotation PA166311672",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215852,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311676",
      "name": "Recommendation Annotation PA166311676",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215856,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers. Should CEREBYX [fosphenytoin] be utilized for CYP2C9*3 carriers, consider starting at the lower end of the dosage range...[P]atients who are known to be intermediate or poor metabolizers may ultimately require lower doses to maintain similar steady-state concentrations compared to normal metabolizers. In patients who are known to be carriers of the decreased function CYP2C9*2 or *3 alleles (intermediate and poor metabolizers), consider starting at the low end of the dosage range and monitor serum concentrations to maintain total phenytoin concentrations of 10 to 20 mcg/mL.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311682",
      "name": "Recommendation Annotation PA166311682",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215861,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers. Should CEREBYX [fosphenytoin] be utilized for CYP2C9*3 carriers, consider starting at the lower end of the dosage range...[P]atients who are known to be intermediate or poor metabolizers may ultimately require lower doses to maintain similar steady-state concentrations compared to normal metabolizers. In patients who are known to be carriers of the decreased function CYP2C9*2 or *3 alleles (intermediate and poor metabolizers), consider starting at the low end of the dosage range and monitor serum concentrations to maintain total phenytoin concentrations of 10 to 20 mcg/mL.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311686",
      "name": "Recommendation Annotation PA166311686",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215865,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers. Should CEREBYX [fosphenytoin] be utilized for CYP2C9*3 carriers, consider starting at the lower end of the dosage range...[P]atients who are known to be intermediate or poor metabolizers may ultimately require lower doses to maintain similar steady-state concentrations compared to normal metabolizers. In patients who are known to be carriers of the decreased function CYP2C9*2 or *3 alleles (intermediate and poor metabolizers), consider starting at the low end of the dosage range and monitor serum concentrations to maintain total phenytoin concentrations of 10 to 20 mcg/mL.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311673",
      "name": "Recommendation Annotation PA166311673",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215853,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "1.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311675",
      "name": "Recommendation Annotation PA166311675",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215855,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311801",
      "name": "Recommendation Annotation PA166311801",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215980,
        "html": "<p>&quot;[P]atients who are known to be intermediate or poor metabolizers may ultimately require lower doses to maintain similar steady-state concentrations compared to normal metabolizers. In patients who are known to be carriers of the decreased function CYP2C9*2 or *3 alleles (intermediate and poor metabolizers), consider starting at the low end of the dosage range and monitor serum concentrations to maintain total phenytoin concentrations of 10 to 20 mcg/mL.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311671",
      "name": "Recommendation Annotation PA166311671",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215851,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 positive",
        "CYP2C9": "0.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311708",
      "name": "Recommendation Annotation PA166311708",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215888,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers. Should CEREBYX [fosphenytoin] be utilized for CYP2C9*3 carriers, consider starting at the lower end of the dosage range...[P]atients who are known to be intermediate or poor metabolizers may ultimately require lower doses to maintain similar steady-state concentrations compared to normal metabolizers. In patients who are known to be carriers of the decreased function CYP2C9*2 or *3 alleles (intermediate and poor metabolizers), consider starting at the low end of the dosage range and monitor serum concentrations to maintain total phenytoin concentrations of 10 to 20 mcg/mL.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "No Result",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311677",
      "name": "Recommendation Annotation PA166311677",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215857,
        "html": "<p>&quot;Consider avoiding CEREBYX [fosphenytoin] as an alternative to carbamazepine in patients who are positive for HLA-B*1502 or in CYP2C9*3 carriers. Should CEREBYX [fosphenytoin] be utilized for CYP2C9*3 carriers, consider starting at the lower end of the dosage range...[P]atients who are known to be intermediate or poor metabolizers may ultimately require lower doses to maintain similar steady-state concentrations compared to normal metabolizers. In patients who are known to be carriers of the decreased function CYP2C9*2 or *3 alleles (intermediate and poor metabolizers), consider starting at the low end of the dosage range and monitor serum concentrations to maintain total phenytoin concentrations of 10 to 20 mcg/mL.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166311741",
      "name": "Recommendation Annotation PA166311741",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA164746820",
          "name": "fosphenytoin",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452215920,
        "html": "<p>&quot;[P]atients who are known to be intermediate or poor metabolizers may ultimately require lower doses to maintain similar steady-state concentrations compared to normal metabolizers. In patients who are known to be carriers of the decreased function CYP2C9*2 or *3 alleles (intermediate and poor metabolizers), consider starting at the low end of the dosage range and monitor serum concentrations to maintain total phenytoin concentrations of 10 to 20 mcg/mL.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "HLA-B": "*15:02 negative",
        "CYP2C9": "1.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product CEREBYX (Fosphenytoin Sodium), NDA020450, Pfizer Laboratories Div Pfizer Inc",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020450"
    }
  ],
  "version": "2024-03-08-14-34"
}